Alice Indini

What is the real benefit of adjuvant therapy in stage II and III melanoma? A group of experts critically reviewed the results so far reported. A must read article to guide therapeutic choices in a debated setting! #IAmPractisingOncologist #melanoma ejcancer.com/article/S0959-…

Great job, #Iampractisingoncologist! We r the @esmo_eur_oncology commitee involved in feeling the gap between research and daily clinical practice. If you have a full 8-hours clinic and look4a way to be updated on what’s going on in the oncology field, welcome on board!

Alexios Matikas, OncologyPRO Working Group Member & ESMO #YoungOncologist Committee Member, on why OncologyPRO is an essential tool to help oncologists in their #dailypractice, thanks to its accessibility, ease of use, and content depth. ow.ly/pmwU50M9esW #oncology

Great job from the Practising Oncologist Working Group! Very useful!!!!

Calling all practising oncologists 📢 Take the ESMO Practising Oncologists Working Group survey so we can better understand your practice needs & opinions on current products. ow.ly/FS3650KMUi7 @brasiuniene @DrMeredithGT @LazarPo31787807 @BennounaJaafar @G_LipositsMD

@brasiuniene I’ll see you there!

Beautiful day on the way😉 #ESMO22 #ESMO2022 #oncology #medicaloncology

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. pubmed.ncbi.nlm.nih.gov/35752398/

Our study on #mucosal #melanoma is now online in @Annals_Oncology - Although retrospective, this study represents the largest report to date analyzing the efficacy of ICIs in this rare cancer that carries a poor prognosis. Here are some key points:

Soft Tissue #Sarcomas Webinar ⏰ 29/3, 18:30 CEST Registration open for this live discussion of a real-world case. Live viewers: certificate of attendance & 1 ESMO-MORA point Full info 🔗 ow.ly/YIT950ImoNY @AliceIndini @SilviaStacchia @pawel_sobczuk @jeanyvesblay #scmsm

#ESMOPreceptorship on Molecular #CancerBiology for Practising Oncologists & #Cancer Treatment De-escalation 2022: Multidisciplinary management, standards of care & future perspectives ow.ly/pgJv50HQFsZ @BennounaJaafar @brasiuniene @PietDirix @G_LipositsMD @LazarPo31787807

Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. bit.ly/3GkSqZK @Ludwig_Cancer

On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy nejm.org/doi/full/10.10…

👉 Check out the @myESMO Practicing Oncologists Working Group's new series of Spotlight presentations featuring highlights from #ESMO21 oncologypro.esmo.org/meeting-resour…

Mucosal melanomas: molecular profile and therapy. What physicians need to know!!

New #JITC article: Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties bit.ly/3pW3yFk @SripadRam

Do not miss! clustersrl.it/res-wfsc?fbcli…